



## Program 14<sup>th</sup> Meeting of the IBCN

October 27-29<sup>th</sup>, 2016, Bochum, Germany

### THURSDAY, OCTOBER 27<sup>TH</sup>, 2016

18:00 Welcome Dinner (*Renaissance Hotel*)

### FRIDAY, OCTOBER 28<sup>TH</sup>, 2016

Introduction	Topic	Speaker
07:30 - 08:00	Registration/Light breakfast	
08:00 - 08:15	Welcome to IBCN Meeting	Goebell/Kamat
08:15 - 08:20	Welcome to Bochum	Brüning/Pesch

Pipeline	Topic	Chair: Goebell
08:20 - 08:40	BMS: Immuno-oncologic approaches to bladder cancer	TBA
08:40 - 08:50	<b>Discussion</b>	

Pipeline	Topic	Chair: Kamat
08:50 - 09:10	Roche: Atezolizumab Clinical Development in NMIBC	Legrand
09:10 - 09:20	<b>Discussion</b>	

Targeting novel pathways	Topic	Chair: Kamat
09:20 - 09:27	Oncofetal glycan, chemoresistance	Daugaard (* <i>Travel Award</i> *)
09:27 - 09:34	HER2 and EGFR amplification and expression	Eriksson
09:34 - 09:41	Chick embryo chorioallantoic membrane assay	Skowron
09:41 - 09:48	Inhibition of protein kinase D as a therapy for bladder cancer	Agarwal
09:48 - 10:03	<b>Discussion</b>	
10:03 - 10:10	Systemic therapy for urachal carcinoma	Szarvas
10:10 - 10:17	Understanding of therapy resistance to CDK4/6 inhibitors	Nawroth
10:17 - 10:24	Intratumoral anti-CTLA4 administration	Mangsbo
10:24 - 10:31	IMvigor 210 first line atezolizumab cisplatin ineligible	Necchi
10:31 - 10:50	<b>Discussion</b>	



## Program 14<sup>th</sup> Meeting of the IBCN

October 27-29<sup>th</sup>, 2016, Bochum, Germany

**FRIDAY, OCTOBER 28<sup>TH</sup>, 2016**

### Break 10:50 – 11:05

Pipeline	Topic	Chair: Black
11:05 – 11:25	H3 Biomedicine: Evasion of immunosurveillance by genomic alterations of PPAR $\gamma$ /RXR $\alpha$	Korpál
11:25 – 11:35	<b>Discussion</b>	

Virus Therapy	Topic	Chair: Nawroth
11:35 – 11:55	The multi-faceted mechanism of tumor suppression by oncolytic parvoviruses	Rommelaere
11:55 – 12:10	Virotherapy plus PD-L1 inhibition	Holm
12:10 – 12:25	AdIFN for BCG unresponsive NMIBC	Dinney
12:25 – 12:45	<b>Discussion</b>	

### Lunch Break 12:45 – 13:30

Pipeline	Topic	Chair: Kamat
13:30 – 13:50	TARIS Technology Update in Urothelial Carcinoma	Cutie
13:50 – 14:00	<b>Discussion</b>	

Diagnosis & Risk Stratification	Topic	Chair: Schmitz-Dräger
14:00 – 14:15	Label-free imaging of bladder cancer: towards automated differential diagnostics	Klaus Gerwer
14:15 – 14:20	<b>Discussion</b>	
14:20 – 14:27	Tele-cystoscopy	Krupski
14:27 – 14:34	Diagnostic algorithms for asymptomatic microhematuria	Kuckuck
14:34 – 14:41	UroFollow Biobank	Johnen
14:41 – 14:50	<b>Discussion</b>	
14:50 – 14:57	T1 substaging	van Rhijn
14:57 – 15:04	Pathologic risk stratification of T1 bladder cancer	Hansel
15:04 – 15:10	<b>Discussion</b>	
15:10 – 15:17	CTC pilot study	Culp



## Program 14<sup>th</sup> Meeting of the IBCN

October 27-29<sup>th</sup>, 2016, Bochum, Germany

<b>15:17 – 15:24</b>	ctDNA in metastatic bladder carcinoma	Todenhöfer
<b>15:24 – 15:30</b>	<b>Discussion</b>	

Industry meets IBCN	Topic	Chair: Schmitz-Dräger
<b>15:30</b>	Breakout groups	

**Adjourn 16:30**

### Reconvene for Dinner 18:30

<b>17:45</b>	Bus transfer from Renaissance Hotel
<b>18:30</b>	Tour of Heinrichshütte (Museum)
<b>20:00</b>	Dinner at Heinrichs <a href="https://www.lwl.org/industriemuseum/standorte/henrichshuette-hattingen/english">https://www.lwl.org/industriemuseum/standorte/henrichshuette-hattingen/english</a>
<b>2230</b>	Return bus transfer to Renaissance Hotel

## **SATURDAY, OCTOBER 29<sup>TH</sup>, 2016**

Business Meeting	Topic	Speaker: Goebell/Kamat
<b>08:00-09:00</b>	IBCN Business Meeting with light breakfast <i>(breakfast also available for those not attending the meeting)</i>	

Keynote Lecture	Topic	Chair: Black
<b>09:00 – 09:30</b>	Animal Models of Bladder Cancer	Cory Abate-Shen
<b>09:30 – 09:40</b>	<b>Discussion</b>	

Potpourri	Topic	Chair: Goebell
<b>09:40 – 09:47</b>	Phase I trial of rBCG	Rentsch
<b>09:47 – 09:54</b>	Treatment of oligometastatic bladder cancer	Navai
<b>09:54 – 10:01</b>	Collaborative Effort in Bladder Sarcoma Research	Luz
<b>10:01 – 10:08</b>	IBCN recommendations for MIBC follow-up	Kamat



## Program 14<sup>th</sup> Meeting of the IBCN

October 27-29<sup>th</sup>, 2016, Bochum, Germany

<b>10:08 – 10:20</b>	<b>Discussion</b>	
<b>10:20 – 10:27</b>	Uncovering the TWEAK/Fn14 cytokine-receptor axis in bladder cancer	Sanchez-Carbayo
<b>10:27 – 10:34</b>	CD4+ expansion after BCG	Bivalacqua
<b>10:34 – 10:41</b>	Myeloid derived suppressor cells	Grivas (*Travel Award*)
<b>10:41 – 10:50</b>	<b>Discussion</b>	

**Break 10:50 – 11:05**

Molecular Subtyping	Topic	Chair: Black
<b>11:05 – 11:17</b>	Molecular subtyping of advanced bladder cancer	Sjödahl
<b>11:17 – 11:29</b>	TCGA Update	Lerner
<b>11:29 – 11:41</b>	Molecular subtypes and response to immune therapy in NMIBC	McConkey
<b>11:41 – 11:53</b>	Response to neoadjuvant chemotherapy in MIBC is dependent on molecular subtypes	Seiler
<b>11:53 – 12:10</b>	<b>Discussion</b>	
<b>12:10 – 12:22</b>	Subtype specific bladder mouse models	Kim
<b>12:22 – 12:34</b>	Validation of 12 gene progression score in NMIBC	Dyrskjot
<b>12:34 – 12:46</b>	Molecular subtypes in micropapillary urothelial carcinoma	Guo
<b>12:46 – 12:58</b>	Forerunner genes - basa to luminal differentiation checkpoint	Czerniak
<b>12:58 – 13:15</b>	<b>Discussion</b>	

**Lunch Break 13:15 – 14:00**

Urine Biomarkers	Topic	Chair: Zwarthoff
<b>14:00 – 14:07</b>	Urinary gene expression test	Mengual
<b>14:07 – 14:14</b>	Epigenetic markers in tissue and urine	Smit
<b>14:14 – 14:21</b>	Hypermethylation of 4 gene panel for prediction of progression of NMIBC	van Kessel
<b>14:21 – 14:28</b>	Urine proteomic biomarker panel	Vlahou
<b>14:28 – 14:35</b>	Survivin and UBC Rapide for	Gleichenhagen



## Program 14<sup>th</sup> Meeting of the IBCN

October 27-29<sup>th</sup>, 2016, Bochum, Germany

	detection of bladder cancer	
<b>14:35 - 14:50</b>	<b>Discussion</b>	

<b>Chromatin Remodeling</b>	<b>Topic</b>	<b>Chair: Nawroth</b>
<b>14:50 - 15:10</b>	Functional analysis of chromatin remodeling genes	Schulz
<b>15:10 - 15:17</b>	Chromatin remodeling gene mutations and T-cell infiltration	Sfakianos
<b>15:17 - 15:32</b>	Genome-wide RNAi screen identifies novel ploidy-control genes that associate with recurrent mutations in human cancer	Günes
	<b>Discussion</b>	

<b>Wrap-Up &amp; Closing Remarks</b>	
<b>16:00</b>	Kamat and Goebell